I. Roibás Veiga , P. Méndez Brea , T. González Vidal , C. Vidal Pan
{"title":"Protocolo diagnóstico y terapéutico de la esofagitis eosinofílica","authors":"I. Roibás Veiga , P. Méndez Brea , T. González Vidal , C. Vidal Pan","doi":"10.1016/j.med.2025.04.008","DOIUrl":null,"url":null,"abstract":"<div><div>A diagnostic and therapeutic protocol for eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus driven by a type 2 immune response, is presented. This protocol establishes precise clinical, endoscopic, and histopathological criteria for diagnosis and outlines a stepwise treatment approach, including proton pump inhibitors, topical corticosteroids, elimination diets, and biologic therapy for refractory cases. Additionally, emerging biomarkers are highlighted, and the importance of endoscopic and functional monitoring is emphasized to prevent fibrostenotic complications and optimize therapeutic outcomes.</div></div>","PeriodicalId":100912,"journal":{"name":"Medicine - Programa de Formación Médica Continuada Acreditado","volume":"14 29","pages":"Pages 1775-1780"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine - Programa de Formación Médica Continuada Acreditado","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304541225000757","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
A diagnostic and therapeutic protocol for eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus driven by a type 2 immune response, is presented. This protocol establishes precise clinical, endoscopic, and histopathological criteria for diagnosis and outlines a stepwise treatment approach, including proton pump inhibitors, topical corticosteroids, elimination diets, and biologic therapy for refractory cases. Additionally, emerging biomarkers are highlighted, and the importance of endoscopic and functional monitoring is emphasized to prevent fibrostenotic complications and optimize therapeutic outcomes.